Business Wire

Keeping Connectivity Within Reach, OPPO Launches Its First Smartwatch With Thales’ eSIM Solutions

Share

OPPO, the world's leading smart device manufacturer, has selected Thales’ set of eSIM products and services for its OPPO Watch, the brand’s first smartwatch series with built-in cellular connectivity. The launch of the OPPO Watch marks a strategic step into the field of IoT for the company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200906005025/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

OPPO Watch © OPPO

One of the most compelling features of the OPPO Watch is the eSIM-based cellular connectivity. Thales’ eSIM allows OPPO Watch users to enjoy a smoothly digital experience by activating a mobile subscription remotely and always stay connected without having to tether it to a mobile phone. Users can make voice calls or send messages at any time directly through the smartwatch, providing seamless connectivity during workouts or other situations where carrying a mobile phone is inconvenient. This smooth experience leverages Thales eSIM solutions to offer a full range of subscription services during the life cycle of the device.

By eliminating the need for an additional SIM card slot, Thales’ eSIM makes sleek mobile-connected smartwatches possible. Indeed it enables a thinner and lighter smartwatch design while freeing up more space for extra features such as up to 50 meter water resistance. It thereby helps OPPO fulfil its mission of elevating life through technological artistry.

The Thales embedded SIM has been qualified by all three China’s mobile operators allowing OPPO smartwatch users to select their mobile subscription from any of these operators.

“As OPPO's first foray into the wearable electronics market, the OPPO Watch marks a strategic step into the field of AIoT (Artificial IoT) for the company. Thanks to Thales' eSIM solutions that bring smartphone-level convenience to smartwatches, users can stay connected in a smarter and more efficient way without restrictions. We are looking forward to working with Thales again, given their leadership in eSIM and the success of our current partnership.”
Liu Bo, President of OPPO China

“The wearable segment is the second largest market for eSIM-compliant consumer electronics after smartphones. ABI Research forecasts that a total of 315 million cellular enabled wearables will have shipped by 2025. Smartwatch makers, in particular, are increasingly on-boarding eSIM connectivity in their flat-design devices to address new smartwatch-only use cases such as kids safety, sports and health monitoring...”
David McQueen, Director, Connected Consumer Devices, ABI Research Research

“Thales is honoured to provide a full suite of eSIM solutions for OPPO Watch. AIoT is one of OPPO’s key focuses aiming to bring customers seamless experiences to their daily life, including sport and health. Thales is OPPO’s key eSIM solutions partner, empowering them with instant connectivity for their consumer devices. We are proud to accompany OPPO on this journey and fully support their ambitions of providing their users with the best innovations available.”
Jérôme Bendell, Vice President of Thales North Asia and CEO of Thales in China

Thales is the world's leader in eSIM connectivity management with more than 200 eSIM management platforms awarded by mobile operators, operator alliances, MVNOs, automotive makers, and OEMs across all continents.

Related resources:
What is an eSIM: 6 illustrated answers infographic
4 ways to activate eSIM-capable consumer IoT devices dossier
Best practices for optimising eSIM adoption eBook
Innovative eSIM use cases such as prepaid offers for inbound travelers and family bundle
dossier

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).

Thales is investing in particular in digital innovations – connectivity, Big Data, artificial intelligence and cybersecurity – technologies that support businesses, organisations and governments in their decisive moments.

About Thales in China

Thales provides innovative solutions for the infrastructure that forms the backbone of China’s growth. The Group has been present in China for around 40 years and is the trusted partner for the Chinese aviation and urban rail transportation industries. In the meanwhile, from secure software to biometrics and encryption, Thales has successfully applied its advanced technology to mobile communication, banking, IoT and software monetization etc. Thales has 3 JVs and employs 2,300 people with offices located in 8 cities in China. Thales established R&D centers and Innovation Hubs in Beijing, Dalian and Hong Kong to provide innovative solutions for both China and international market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS
Head of Government Affairs & Communications
Thales in China
Tammy Qiu
+86 10 65875066
tammy.qiu@asia.thalesgroup.com

Thales, Media Relations
Digital Identity & Security
Vanessa Viala
+33 6 07 34 00 34
vanessa.viala@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye